

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	NA

Apokyn (apomorphine)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Apokyn (apomorphine subcutaneous solution) Kynmobi (apomorphine sublingual film)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Apokyn (apomorphine subcutaneous solution) or Kynmobi (apomorphine sublingual film) may be approved if the following criteria are met:

- I. Individual has a diagnosis of advanced Parkinson's disease; **AND**
- II. Individual is using for the acute, intermittent treatment of hypomobility "off" episodes*; **AND**
- III. Individual is using in conjunction with an antiemetic (excluding 5HT₃ antagonist agents) during initiation period.

Apokyn (apomorphine subcutaneous solution) or Kynmobi (apomorphine sublingual film) may **not** be approved for:

- I. Requests for Erectile Dysfunction (ED).

***Note:** Off episodes refer to the "end-of-dose wearing off" and unpredictable "on/off" episodes.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 6, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.

CRX-ALL-0622-20

PAGE 1 of 2 11/20/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	NA

5. Parkinson's Disease in Adults. NICE Guideline [NG71]. National Institute for Health and Care Excellence. Published Date July 2017. Available at: <https://www.nice.org.uk/guidance/ng71>. Accessed on July 6, 2020.
6. Pahwa R, Factor SA, Lyons KE, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology. 2006; 66(7):983-995. Accessed July 6, 2020.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.